J. Jaso, D.A. Thomas, K. Cunningham, J.L. Jorgensen, H.M. Kantarjian, L.J. Medeiros. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer (ISSN: 1097-0142). 2011; 117 (17) : 4009-17.

R. Alaggio, C. Amador, I. Anagnostopoulos, A.D. Attygalle. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36 (7) : 1720-48.

H. Itakura, S.E. Coutre. Acute Lymphoblastic Leukemia in Adults. In: Greer JP, Foerster J, Rodgers GM, Paraskavas F, Glader B, Arber DA, et al., editors. Wintrobe's Clinical Hematology. 12th ed. United State of America: Lippincott Williams & Wilkins; 2008. p. 1820-42. 2008;

C.H. Pui. Acute Lymphoblastic Leukemia. In: Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT, editors. Williams Hematology. 8th ed. United State of America: McGraw-Hill; 2010. p. 2243-78.. 2010;

R.A. Larson, R.K. Dodge, C.P. Burns, E.J. Lee, R.M. Stone, P. Schulman. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood (ISSN: 0006-4971). 1995; 85 (8) : 2025-37.

J. Takeuchi, T. Kyo, K. Naito, H. Sao, M. Takahashi, S. Miyawaki. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia (ISSN: 0887-6924). 2002; 16 (7) : 1259-66.

B. Gleissner, N. Gökbuget, C.R. Bartram, B. Janssen, H. Rieder, J.W. Janssen, German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood (ISSN: 0006-4971). 2002; 99 (5) : 1536-43.

E. Jabbour, H. Kantarjian, F. Ravandi, D. Thomas, X. Huang, S. Faderl. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. The Lancet. Oncology (ISSN: 1474-5488). 2015; 16 (15) : 1547-55.

N. Daver, D. Thomas, F. Ravandi, J. Cortes, R. Garris, E. Jabbour. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica (ISSN: 1592-8721). 2015; 100 (5) : 653-61.

F. Ravandi, S.M. O'Brien, J.E. Cortes, D.M. Thomas, R. Garris, S. Faderl. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer (ISSN: 1097-0142). 2015; 121 (23) : 4158-64.

T. Terwilliger, M. Abdul-Hay. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood cancer journal 2017; 7 (6) : e577-e.

M.D. Tabernero, A.M. Bortoluci, I. Alaejos, M.C. López-Berges, A. Rasillo, R. García-Sanz. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia (ISSN: 0887-6924). 2001; 15 (3) : 406-14.

T.M. Owaidah, F.I. Rawas, M.F. Al Khayatt, N.B. Elkum. Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement. Hematology/Oncology and Stem Cell Therapy (ISSN: 1658-3876). 2008; 1 (1) : 34-7.

G.S. Tang, J. Wu, M. Liu, H. Chen, S.G. Gong, J.M. Yang. BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia. American Journal of Translational Research (ISSN: 1943-8141). 2015; 7 (3) : 632-9.

E.G. van Lochem, V.H. van der Velden, H.K. Wind, J.G. te Marvelde, N.A. Westerdaal, J.J. van Dongen. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry. Part B, Clinical Cytometry (ISSN: 1552-4949). 2004; 60 (1) : 1-13.

C.D. Jennings, K.A. Foon. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood (ISSN: 0006-4971). 1997; 90 (8) : 2863-92.

E. Paietta, J. Racevskis, D. Neuberg, J.M. Rowe, A.H. Goldstone, P.H. Wiernik, Eastern Cooperative Oncology Group/Medical Research Council. Expression of CD25 (interleukin-2 receptor α chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Leukemia (ISSN: 0887-6924). 1997; 11 (11) : 1887-90.

K. Sugita, T. Mori, S. Yokota, M. Kuroki, T.O. Koyama, T. Inukai. The KOR-SA3544 antigen predominantly expressed on the surface of Philadelphia chromosome-positive acute lymphoblastic leukemia cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed in cytoplasm of human leukemia cells. Leukemia (ISSN: 0887-6924). 1999; 13 (5) : 779-85.

O. Hrusák, A. Porwit-MacDonald. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia (ISSN: 0887-6924). 2002; 16 (7) : 1233-58.

Y. Li, D. Zou, Y. Zhao, Y. Mi, J. Wang, L. Qiu. Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China. Leukemia & Lymphoma (ISSN: 1029-2403). 2010; 51 (3) : 488-96.

M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, Japan Adult Leukemia Study Group. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology (ISSN: 1527-7755). 2006; 24 (3) : 460-6.

C.A. Seol, Y.U. Cho, S. Jang, C.J. Park, J.H. Lee, J.H. Lee. Prognostic significance of recurrent additional chromosomal abnormalities in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Genetics (ISSN: 2210-7762). 2017; 216-21729-36.

P.A. Brown, M. Wieduwilt, A. Logan, D.J. DeAngelo, E.S. Wang, A. Fathi. Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. Journal of the National Comprehensive Cancer Network : JNCCN (ISSN: 1540-1413). 2019; 17 (5) : 414-23.

D. Hoelzer, R. Bassan, H. Dombret, A. Fielding, J.M. Ribera, C. Buske, ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society for Medical Oncology (ISSN: 1569-8041). 2016; 27v69-82.

A. Lahjouji, F. Bachir, S. Bennani, S. Benchekroun, S.A. e. Clinical importance of myeloid antigen expression in Moroccan patients with adult B-lineage acute lymphoblastic leukemia. Neoplasma (ISSN: 0028-2685). 2013; 60 (5) : 553-60.

S. Rodríguez-Rodríguez, A. Pomerantz, R. Demichelis-Gómez, G. Barrera-Lumbreras, O.V. Barrales-Benítez, X. Lopez-Karpovitch. Impact of aberrant antigens in the outcome of patients with acute leukemia at a referral institution in Mexico City. Revista de investigación clínica (ISSN: 0034-8376). 2016; 68 (6) : 305-13.

E. Supriyadi, A.J. Veerman, Sutaryo, I. Purwanto, P.M. Vd Ven, J. Cloos. Myeloid antigen expression in childhood acute lymphoblastic leukemia and its relevance for clinical outcome in Indonesian ALL-2006 protocol. Journal of Oncology (ISSN: 1687-8469). 2012; 2012

K. Blatt, I. Menzl, G. Eisenwort, S. Cerny-Reiterer, H. Herrmann, S. Herndlhofer. Phenotyping and target expression profiling of CD34+/CD38- and CD34+/CD38+ stem-and progenitor cells in acute lymphoblastic leukemia. Neoplasia : An International Journal for Oncology Research (ISSN: 1476-5586). 2018; 20 (6) : 632-42.